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Introduction
In patients with systemic diseases bone mineral density is
diminished due to the underlaying disease, the secondary
loss of bone mass, the diminution of mobility and the
treatment with steroids. Biphosphonates inhibit bone
resorption: they produce reduction of the apoptosis in
osteoblasts and induce apoptosis in osteoclasts [1,2].
Objective
To value the effectiveness of the treatment with intrave-
nous pamidronate in children with secondary osteoporo-
sis or osteopenia to rheumatic diseases.
Materials and methods
Retrospective analytical study: 22 children, ages between
the 4 and 17 years and clinical diagnosis of osteopenia,
osteoporosis, calcinosis secondary to rheumatic diseases
(Juvenile Idiopatic Arthritis, Systemic Lupus Erythemato-
sus, Juvenile Dermatomiositis, Overlap Syndrome, Panar-
teritis Nodosa, Familiar Mediterranean Fever). Criteria of
inclusion: the patients had to fulfill the criteria of osteope-
nia and osteoporosis defined according to z-score or bone
mineral density; and the diagnostic criteria of the referred
diseases. Information about the underlaying disease, the
treatment received and steroids' dose and duration was
collected. The administration of intravenous pamidronate
was made according to the protocol established by Glo-
rieux et al.
Results
All the patients treated with intravenous pamidronate pre-
sented a significant increase in bone mineral density, clin-
ical improvement, decrease of the number of fractures,
reduction in bone pain and improvement of the quality of
life. In all the patients with calcinosis a reduction was
observed and in one patient it even disappeared.
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